Standard treatment improves prognosis of patients with stage ⅡB/Ⅲ synovial sarcoma:Report of 76 cases

CHEN Yong,YANG Yun,WANG Chun-meng,SHI Ying-qiang
DOI: https://doi.org/10.3969/j.issn.1007-3639.2012.09.011
2012-01-01
Abstract:Background and purpose:There is no universally accepted treatment for stage ⅡB/Ⅲ soft tissue sarcomas,the aim of our study was to investigate the clinical characteristics of synovial sarcoma patients and their therapeutic modalities.The influence of treatment on prognosis was retrospectively analyzed.Methods:Seventy-six cases of stage ⅡB/Ⅲ synovial sarcoma accepted the treatment in Department of Bone and Soft Tissue Tumors in Tianjin Medical University Cancer Institute and Hospital between Jan.1993 and Dec.2008 were retrospectively analyzed.All 76 patients were treated with surgical resection.Based on the American Joint Committee on Cancer(AJCC) Staging 2010 Soft Tissue Tumor Staging System and the Guidelines for treatment of soft tissue tumors from National Comprehensive Cancer Network(NCCN) published in 2011,the patients were divided into standardized treatment(ST) group(n=45) and non-standardized treatment(NST) group(n=31),the clinical,pathologic,and therapeutic variables were analyzed for disease-specific survival(DSS),local recurrence-free survival(LRFS) and distant recurrence-free survival(DRFS).Results:The clinical and pathological characteristics of the ST group patients were similar to those of NST group patients.The 5-year DSS of the ST group patients was 71%,which was 41% for the NST group patients.The 10-year DSS of the ST group patients was 53%,which was significant higher than that of NST group patients(37%,P<0.05).Multivariate analysis indicated that patients in ST group had an improved 5-year DSS(71% vs 41%),LRFS(84% vs 63%) and DRFS(62% vs 33%).Conclusion:Synovial sarcoma requires multimodality treatment.Patients with high risk synovial sarcomas may benefit from the ST.
What problem does this paper attempt to address?